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Abstract 
It has recently been shown that aliphatic sulphonamides are good inhibitors of carbonic anhydrase (CA) provided that he pK of the sulphonamide 
is low. We have determined the structure of the complex between CAII and CF3SO2NH2 by X-ray crystallographic methods. The nitrogen of the 
sulphonamide is bound to the zinc ion of the enzyme in the usual manner. The other parts of the inhibitor show a different mode of binding from 
aromatic sulphonamides since the trifluoromethyl group is bound at the hydrophobic part of the active site instead of pointing out from the active 
site. It should be possible to design ew inhibitors pecific for the different isoenzymes, starting from the present structure. 
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1. Introduction 
Carbonic anhydrase (carbonate hydro-lyase, EC 
4.2.1.1) is a zinc enzyme that catalyzes the interconver- 
sion of  CO2 and HCO3 in a variety of  organisms and 
tissues. Out of  the seven known mammal ian isoenzymes 
[1], CAI ,  CA l l  and CAI I I  [2~1] have been investigated 
crystallographically. As expected from the high degree of  
homology between these 30 kDa isoenzymes [1,5], they 
have analogous three dimensional structures, which re- 
semble that of  a hamburger, with a central fl-sheet run- 
ning through the molecule surrounded on both sides 
mostly by non-helical structures. The active site is in a 
cavity situated on the fl-sheet. The active site zinc ion is 
tetrahedrally coordinated by three histidine residues be- 
longing to this fl-sheet [3] and a water/hydroxide mole- 
cule which in the high activity form CA l l  has a pK of  
around 7 [6]. In addition to high resolution refinement 
of  free CA l l  many ligand complexes of  this isoenzyme 
have been analyzed including several sulphonamides as 
well as the structure of  mutants and metal substituted 
derivatives (reviewed in [7]). The inhibitor/substrate 
binding position is between the zinc and a part of  the 
fl-sheet consisting of  hydrophobic side chains in a very 
stable and rigid stucture. The zinc water/hydroxide posi- 
tion can normally be occupied only by hydrogen bond 
donors due to the nearby lone pair of  the T1990~,1. The 
central step in all mechanistic models discussed today is 
the nucleophilic attack by the zinc bound hydroxide on 
the carbon dioxide carbon atom [7-12]. 
The interaction between carbonic anhydrase and the 
sulphonamides i of  significant medical interest. Inhibi- 
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tion of  carbonic anhydrase in the ciliary process by 
sulphonamide inhibitors is effective in the treatment of  
glaucoma [13,14]. Side effects caused by high doses of  
systemic drugs have urged the creation of  a new genera- 
tion of  sulphonamide inhibitors which could be intro- 
duced topically in smaller amounts [13,15]. The common 
denominator of  the sulphonamide drugs is the -SO2NH2 
group. Aromatic sulphonamides normally bind strongly 
to the enzyme whereas aliphatic sulphonamides bind 
more weakly. However, recently Maren and Conroy 
discovered that trif luoromethane sulphonamide 
(CF3SO2NH2) has a pK  of  5.9 and a carbonic anhydrase 
II dissociation constant of  2 nM and that the dissociation 
constant of  aliphatic sulfonamides i strongly related to 
the pK  [14]. The affinity of  this inhibitor for low activity 
forms of  carbonic anhydrase is also unusually high. The 
structure of  this inhibitor in complex with human car- 
bonic anhydrase II is the topic of  the present paper. 
2. Materals and methods 
2.1. Crystallization and soaking 
Human carbonic anhydrase II was crystallized as described previ- 
ously in 2.4 M ammonium sulphate, 50 mM Tris-HCl, pH 8.5, and 1 
mM HgCI 2 [16]. Trifluoromethane sulphonamide was supplied by the 
Minnesota Mining and Manufacturing Company. The HCAII crystals 
were soaked in 3 M ammonium sulphate, 50 mM Tris, pH 7.8, for two 
days with 5 mM fl-mercaptoethanol i  rder to remove the mercury and 
subsequently for two days with 1 mM CF3SO2NH 2. 
2.2. Data collection and processing 
X-ray diffraction data were collected with a Siemens area detector 
system using a Rigaku RU200BEH rotating anode running at 40 kV 
and 100 mA with a 0.3 mm focus as the X-ray source. A graphite 
monochromator was used to obtain CuK~ radiation. The detector to 
crystal distance was 8.5 cm and the collimator width 0.5 mm. The 
goniostat was a Siemens three-axis system and 20 was set to 17 °. The 
crystal was rotated 185 ° around to with a step size of 0.25 ° and 150 s 
exposure time per frame. The procedure was repeated after changing 
(a by 90 °. A single crystal was used for the entire data set. The program 
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package Xengen [17] was used for data reduction. Data collection 
statistics are shown in Table 1. 
2.3. Refinement and graphics 
Restrained least square refinement [18] was performed at 1.93 /k 
resolution using the program PROFFT [19]. The starting model was the 
native HCAII structure [9] where some of the active site water mole- 
cules were removed. 21Fol-IFcl and IFol-IFc[ electron density maps 
were calculated with the CCP4 program suite [20]. The refinement was 
performed iteratively with graphics work where inhibitor and solvent 
molecules were inserted successively to fit the calculated maps prior to 
the next series of refinement cycles. The results were visualized on an 
Evans and Sutherland ESV graphics tation using the program O [21]. 
Plots were prepared by the program ESVodo [22]. Temperature factors 
were refined isotropically. Coordinate root mean-square deviations 
were estimated from Luzzati plots [23]. Refinement s atistics are shown 
in Table 2. Coordinates and F values have been deposited with the 
Protein Data Bank, Chemistry Department, Brookhaven National 
Laboratory, Upton, NY 11973, USA, from which copies are available 
[24]. The accession umber is IBCD. 
3. Results and discussion 
The active site structure of the HCAII trifluorom- 
ethane sulphonamide complex is shown in Fig. 1. A com- 
parision between the present rifluoromethane sulpho- 
namide binding and that of the aromatic sulphonamide 
acetazolamide [25] is shown in Fig. 2. The positions for 
the sulphonamide nitrogen atoms are similar, but com- 
pared to acetazolamide, the trifluoromethane sulpho- 
namide inhibitor is rotated 180 ° around the sulphur- 
nitrogen bond. As a result, both oxygens of the 
trifluoromethane sulphonamide inhibitor are oriented 
more outwards from the active site cleft differing from 
the closest oxygens in acetazolamide with 2.0 and 2.5 A. 
Likewise, the orientation of the aliphatic trifluoromethyl 
group differs markedly from that of the aromatic ring in 
acetazolamide, the former pointing inward and the latter 
outward from the active site cleft. The smaller aliphatic 
group can make close contacts in the hydrophobic part 
of the active site which is impossible for bulky aromatic 
groups. Its fluoro atoms are within 4 A of several of the 
hydrophobic active site residues like Vale2 l, Val m, 
LeUl9s, Thr199, Trp2o9 and a water molecule (OHH 461) 
as well as the zinc ion and its ligands. 






Mean B (A 2) 13.3 
Error in coordinates (A) 0.17 
according to Luzzati plot 
RMS values 
Distances 
Bond distance (A) 0.020 0.020 
Angle distance (A) 0.030 0.039 
Planar 1~, distance (A) 0.050 0.049 
Miscellaneous 
Plane groups (A) 0.020 0.019 
Chiral centers (A 3) 0.150 0.215 
Non-bonded istances 
Single torsion (A) 0.200 0.157 
Multiple torsion (A) 0.200 0.165 
Possible X Y H bond (A) 0.200 0.160 
Torsion angles 
Planar (°) 3.0 3.4 
Staggered (°) 15.0 16.6 
Orthonormal (°) 20.0 30.8 
Thermal restraints 
Main-chain bond (A 2) 1.000 0.978 
Main-chain angle (A 2) 1.500 1.537 
Side-chain bond (A 2) 1.500 1.979 
Side-chain angle (A 2) 2.000 2.970 
_ Z IFol-lFcl 
Rcr,t Z IFol 
Water molecules 263, 318, 338 and 389 are replaced by 
the inhibitor. Water molecule 292 is also absent in the 
inhibitor-enzyme complex. This water molecule is hy- 
drogen bonded to His 64 in native carbonic anhydrase [9]. 
Instead a new water (OHH499) forms hydrogen bonds 
with His  64, T2000~'l and water 359. This is due to the 
fact that the side chain of His 64 is rotated 180 ° around 
the Cfl-CT' bond from its native conformation [9]. 
As expected, the nitrogen atom of the inhibitor is 
bound directly to the zinc ion with tetrahedral coordina- 
Table 1 
Data collection summary 
Shell lower Number Number Bragg 
limit (A) of scaled of unique possible 
observations reflections 
Completeness Average Average 
to lower intensities l/sig(I) 
limit (%) 
Rsym(%) 
3.50 12,734 3,233 3,252 
2.78 10,099 3,161 3,186 
2.43 8,323 3,091 3,166 
2.21 7,107 2,977 3,141 
2.05 5,966 2,854 3,139 
1.93 2,237 1,467 3,152 
All data 46,466 16,783 19,036 
99.4 288 43.0 6.2 
99.3 142 14.7 10.6 
98.8 77 6.7 16.0 
97.8 58 4.7 19.1 
96.4 45 3.2 22.9 
88.2 39 2.2 27.0 
88.2 118 13.9 8.3 
ZZ I<l>-lil 
Rsy m = 100 yI, where < I> is the average of/~ over all symmetry equivalents. 










Fig. 1. (A) The active site of carbonic anhydrase complexed with the inhibitor CF3SO2NH-. Difference lectron maps were calculated after efinement 
of native coordinates without waters 263,292, 318,338 and 389. Positive (continous lines) and negative (broken lines) [Fo [ - [ Fc[ contours were drawn 
at +3 or. (B) The inhibitor from (A) with all atoms labelled. 
t ion (Table 3) 2 .7 /~ from T199Oyl .  L igands with this 
property  - a negative charge and a proton avai lable on 
the same atom - include OH-  and SH-  in addit ion to 
members o f  the su lphonamide family. These l igands all 
bind strongly [6,13,26] to the zinc water posit ion 
[9,15,25,27,28] because they interact electrostatical ly 
with the zinc ion by virtue of  their negative charge and 
in addi t ion they are hydrogen bond donors to the lone 
pair  of  T199071.  
The O1 atom of  the inhibitor is hydrogen bonded to 
T199N (2.9/~) and makes van der Waals '  contacts with 
several of  the atoms of  residues 198 and 199. The two 
oxygens of  the aromat ic  su lphonamides bind at approx-  
Table 3 
Geometries in the active site of carbonic anhydrase complexed with 
CF3SO2NH- 
Distance His 94 NE2 His 96 N~2 His 119 Nd;1 
CF3SO2NH-N 2.10 115.2 102.9 113.5 
His 94 Ne2 2.17 102.3 116.3 
His 96 N~2 2.25 104.2 
His ]19 Nd;1 2.07 
Distances (Zn-X) and angles (X-Zn-Y) around the zinc ion in ]~ngstrrm 
and degrees. 
imately the same site as cyanate [29], which is isoelec- 
tronic with carbon dioxide whereas the oxygens of  
tr i f luoromethane sulphonamide bind differently. As 
pointed out by Kumar  et al. [30] the su lphonamide group 
can be considered as a transit ion state analogue mimi-  
cing a hydroxide reacting with carbon dioxide. The new 
binding mode raises the question of  which sulphonamide 
complex is the best representat ion of the transit ion state. 
Since most inhibitors bind close to the posit ions of  the 
oxygens of  aromat ic  sulphonamides we are incl ined to 
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Fig. 2. The molecular structure of carbonic anhydrase complexed with 
CF3SO2NH- is compared with the complex with acetazolamide (broken 
lines). The polypeptide chain of the acetazolamide complex [251 is not 
shown since the conformations are virtually the same in the two cases. 
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believe that this is the best representation f the transi- 
tion state [7]. 
Aromatic sulphonamide inhibitors bind more strongly 
to the high activity forms of carbonic anhydrase than to 
the low activity forms [13]. This is true also for the ali- 
phatic trifluoromethane sulphonamide [14] although it is 
bound in a way different from the aromatic sulpho- 
namides. 
In conclusion, the factors giving the trifluoromethane- 
sulphonamide high affinity for carbonic anhydrase is the 
low pK enabling a negatively charged nitrogen to be 
bound to the zinc ion, a small hydrophobic moiety 
placed in the hydrophobic part of the enzyme active site 
and finally the oxygens that are hydrogen bonded (O1) 
or exposed to the solvent (02). Since inhibiton of ciliary 
CAIV is the most critical factor in the in vivo action (in 
rabbits at least) of CF3SO2NH 2 [14] a structural study of 
sulphonamide inhibitors to this isoenzyme in combina- 
tion with the current results may be a useful guide for 
developing new topical sulphonamides for pharmaceuti- 
cal usage. 
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